Hosted by Dailymotion. For legal issues report at the Copyright Center, report us on DMC, or use the Instant Removal tool.
Eli Lilly Raises 2021 Forecast
Description
Eli Lilly ($LLY@US) raised its 2021 profit forecast on Tuesday as it increased sales of its COVID-19 antibody therapies. While the company is best known as the developer and marketer of Prozac, it is also hoping to obtain approval for other drugs. These drugs include an experimental type-2 diabetes drug and a highly anticipated Alzheimer’s drug known only as Donanemab. Eli Lilly shares are up 45% overall in 2021, and the stock rose over half a percent in early trading Tuesday.
Keywords & Tags
#earnings
#finance
#biotech
#covid
#vaccine
#COVID-19
#inflation
#business
#pandemic
#economic recovery
#big pharma
#vaccination
#Eli Lilly
#Delta variant
#pharmaceutical
#prescription drugs
#infections
#economic growth
#hospitalizations
#deaths
#pharmacy
#medical experts
#economic outlook
#2021 Forecast
#Alzheimer’s Drug
#Approval
#increased sales
#Prozac
#type-2 diabetes drug
#Donanemab
More from User
01:02
Karp Sounds Reg Alarm
Benzinga
01:02
SEC Kills PDT
Benzinga
00:56
Walmart Adds Subway Delivery
Benzinga
00:55
GLP-1s Fuel Return Surge
Benzinga
00:52
Hegseth Firm On Anthropic
Benzinga
01:05
Lululemon Falls On Outlook
Benzinga
Related Videos
00:38
Eli Lilly Launches LillyDirect to Address Weight Loss Drug Shortages
Benzinga
00:35
Eli Lilly Slashes Zepbound Prices to Boost Accessibility for Patients and Combat Counterfeit Drugs
Benzinga
00:51
Eli Lilly AI Drug Deal
Benzinga
09:51
Trump Announces Historic Drug Deal With Eli Lilly and Novo Nordisk Through TrumpRx Portal | APT
APT
00:43
Eli Lilly to Cut Prices of Insulin Drugs by 70%
Benzinga
00:48
Eli Lilly accused of bribing doctors to prescribe Mounjaro and other drugs
Straight Arrow News